Revvity Valuation
Is RVTY undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RVTY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: RVTY ($111.11) is trading below our estimate of fair value ($123.26)
Significantly Below Fair Value: RVTY is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RVTY?
Key metric: As RVTY is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is RVTY's PE Ratio? | |
|---|---|
| PE Ratio | 52.4x |
| Earnings | US$258.26m |
| Market Cap | US$13.55b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.7x |
| Enterprise Value/EBITDA | 19.8x |
| PEG Ratio | 2.6x |
Price to Earnings Ratio vs Peers
How does RVTY's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 61.2x | ||
AVTR Avantor | 44.8x | 36.4% | US$13.7b |
QGEN Qiagen | 101.2x | 34.4% | US$9.4b |
TECH Bio-Techne | 74.9x | 21.2% | US$10.9b |
CRL Charles River Laboratories International | 24x | 11.7% | US$9.6b |
RVTY Revvity | 52.4x | 19.8% | US$13.6b |
Price-To-Earnings vs Peers: RVTY is good value based on its Price-To-Earnings Ratio (52.4x) compared to the peer average (61.2x).
Price to Earnings Ratio vs Industry
How does RVTY's PE Ratio compare vs other companies in the US Life Sciences Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
REPC.F RepliCel Life Sciences | 0.02x | n/a | US$136.50k |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: RVTY is expensive based on its Price-To-Earnings Ratio (52.4x) compared to the Global Life Sciences industry average (33.6x).
Price to Earnings Ratio vs Fair Ratio
What is RVTY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 52.4x |
| Fair PE Ratio | 29.5x |
Price-To-Earnings vs Fair Ratio: RVTY is expensive based on its Price-To-Earnings Ratio (52.4x) compared to the estimated Fair Price-To-Earnings Ratio (29.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$111.11 | US$138.84 +25.0% | 8.3% | US$162.17 | US$120.00 | n/a | 18 |
| Nov ’25 | US$121.04 | US$137.90 +13.9% | 8.4% | US$162.17 | US$120.00 | n/a | 18 |
| Oct ’25 | US$124.44 | US$133.87 +7.6% | 7.8% | US$162.00 | US$120.00 | n/a | 18 |
| Sep ’25 | US$122.54 | US$133.87 +9.2% | 7.8% | US$162.00 | US$120.00 | n/a | 18 |
| Aug ’25 | US$125.03 | US$134.10 +7.3% | 7.9% | US$162.00 | US$120.00 | n/a | 17 |
| Jul ’25 | US$103.00 | US$124.04 +20.4% | 9.9% | US$162.00 | US$105.00 | n/a | 16 |
| Jun ’25 | US$109.26 | US$123.67 +13.2% | 10.3% | US$162.00 | US$105.00 | n/a | 16 |
| May ’25 | US$102.60 | US$123.61 +20.5% | 10.3% | US$162.00 | US$105.00 | n/a | 16 |
| Apr ’25 | US$103.27 | US$123.11 +19.2% | 10.6% | US$162.00 | US$100.00 | n/a | 16 |
| Mar ’25 | US$107.12 | US$123.11 +14.9% | 10.6% | US$162.00 | US$100.00 | n/a | 16 |
| Feb ’25 | US$109.26 | US$117.66 +7.7% | 15.1% | US$162.00 | US$85.00 | n/a | 16 |
| Jan ’25 | US$109.31 | US$104.79 -4.1% | 16.5% | US$162.00 | US$85.00 | n/a | 17 |
| Dec ’24 | US$91.28 | US$106.71 +16.9% | 17.0% | US$162.00 | US$85.00 | n/a | 14 |
| Nov ’24 | US$82.54 | US$106.71 +29.3% | 17.0% | US$162.00 | US$85.00 | US$121.04 | 14 |
| Oct ’24 | US$110.70 | US$143.24 +29.4% | 9.9% | US$170.00 | US$120.00 | US$124.44 | 16 |
| Sep ’24 | US$116.92 | US$144.31 +23.4% | 9.1% | US$170.00 | US$125.00 | US$122.54 | 16 |
| Aug ’24 | US$122.63 | US$143.74 +17.2% | 9.9% | US$170.00 | US$120.00 | US$125.03 | 16 |
| Jul ’24 | US$118.79 | US$145.53 +22.5% | 11.1% | US$170.00 | US$120.00 | US$103.00 | 15 |
| Jun ’24 | US$115.67 | US$147.19 +27.3% | 11.4% | US$170.00 | US$120.00 | US$109.26 | 15 |
| May ’24 | US$130.26 | US$155.78 +19.6% | 9.1% | US$182.00 | US$134.00 | US$102.60 | 14 |
| Apr ’24 | US$133.26 | US$158.92 +19.3% | 8.0% | US$182.00 | US$140.00 | US$103.27 | 12 |
| Mar ’24 | US$123.50 | US$158.92 +28.7% | 8.0% | US$182.00 | US$140.00 | US$107.12 | 12 |
| Feb ’24 | US$139.27 | US$160.00 +14.9% | 8.3% | US$185.00 | US$140.00 | US$109.26 | 12 |
| Jan ’24 | US$140.22 | US$157.92 +12.6% | 9.3% | US$178.00 | US$127.00 | US$109.31 | 12 |
| Dec ’23 | US$141.75 | US$156.18 +10.2% | 12.0% | US$192.00 | US$127.00 | US$91.28 | 11 |
| Nov ’23 | US$136.57 | US$166.91 +22.2% | 14.1% | US$202.00 | US$120.00 | US$82.54 | 11 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
IQVIA Holdings
US$34.7b
Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
IQV
US$194.38
7D
-8.1%
1Y
-7.2%
Collegium Pharmaceutical
US$959.4m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
COLL
US$30.00
7D
-0.6%
1Y
15.5%
ANI Pharmaceuticals
US$1.1b
A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.
ANIP
US$55.10
7D
-7.9%
1Y
6.6%